Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
BioSpace5d
Altimmune Jumps On Takeover Rumors After Launching Alcohol Use Disorder Study
The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...
BioSpace7d
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Morningstar5d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, President and COO of Xeris. “American Regent is the ...